Letter: Blood abnormalities during leukaemia treatment.
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D001772:Blood Cell Count; D001854:Bone Marrow Cells; D002648:Child; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000097:blood* / Q000188:drug therapy; D009504:Neutrophils; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D013577:Syndrome
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D011239:Prednisolone; D001215:Asparaginase